fluticasone propionate

(redirected from fluticasone furoate)
Also found in: Dictionary.

fluticasone propionate

Cutivate, Flixonase (UK), Flixotide (UK), Flonase, Flovent Diskus, Flovent HFA

fluticasone furoate

Avamys (CA), Veramyst

Pharmacologic class: Corticosteroid

Therapeutic class: Respiratory inhalant (Flovent, Flonase), anti-inflammatory drug (Cutivate)

Pregnancy risk category C

Action

Unknown. Has potent vasoconstrictive and anti-inflammatory properties.

Availability

fluticasone propionate

Inhalation aerosol, metered (Flovent HFA): 44 mcg, 110 mcg, 220 mcg

Inhalation powder, metered (Flovent Diskus): 50 mcg, 100 mcg, 250 mcg

Nasal spray (Flonase): 50 mcg

Topical cream (Cutivate): 0.005%

Topical ointment (Cutivate): 0.005%

fluticasone furoate

Nasal spray (Veramyst): 27.5 mcg fluticasone furoate in each 50-microliter spray in 10-g bottle containing 120 sprays

Indications and dosages

Prophylaxis of asthma and treatment of asthma for patients requiring oral corticosteroid therapy (Flovent HFA and Flovent Diskus)

Adults and children age 4 and older: Recommended starting dosage and highest recommended dosage, based on prior asthma therapy, are listed in charts below.

Recommended Flovent FHA dosages

For Adults and adolescents age 12 and older

Recommended Flovent Diskus dosages

Seasonal and perennial allergic and nonallergic rhinitis (Flonase)

Adults: Two sprays in each nostril daily or one spray in each nostril b.i.d. After first few days, may reduce dosage to one spray in each nostril daily; some patients may find p.r.n. use of two sprays in each nostril daily effective for symptom control. Maximum dosage is 200 mcg daily (two sprays in each nostril).

Adolescents and children ages 4 and older: Initially, one spray in each nostril daily. If patient doesn't respond, may increase to two sprays in each nostril. Once adequate control is achieved, reduce dosage to one spray in each nostril daily.

Symptoms of seasonal and perennial allergic rhinitis (Veramyst)

Adults and adolescents age 12 and older: 110 mcg (2 sprays per nostril) once daily

Children ages 2 to 11: 55 mcg (1 spray per nostril) once daily

Inflammatory and pruritic manifestations of corticosteroid-responsive atopic dermatoses

Adults and children ages 3 months and older: Apply thin film of Cutivate cream to affected skin area once or twice daily.

Other corticosteroid-responsive dermatoses

Adults and children ages 3 months and older: Apply thin film of Cutivate cream to affected skin area b.i.d.

Contraindications

• Hypersensitivity to drug or its components

• Primary treatment of status asthmaticus or other acute asthma episodes necessitating intensive measures (Flovent FHA, Flovent Diskus)

• Severe allergy to milk proteins (Flovent Diskus)

Precautions

Use cautiously in:

• recurrent epistaxis, recent nasal septal ulcer, nasal surgery, or trauma

• severe hepatic disease (Veramyst)

• glaucoma and cataracts

• tuberculosis; respiratory tract infection; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex

• hypercorticism and adrenal suppression (when used at higher than recommended dosages or in susceptible persons)

• concurrent use of other CYP3A inhibitors (such as ketoconazole; use not recommended with ritonavir)

Candida albicans infection (Flovent, Veramyst)

• elderly patients (Flonase, Veramyst)

• pregnant or breastfeeding patients (Flovent, Flonase, Veramyst)

• children younger age than 4 (Flonase, Flovent)

• children younger than age 2 (Veramyst).

Administration

• Know that Flonase may cause immediate hypersensitivity reaction (contact dermatitis).

• Be aware that topical ointment should be used in adults only.

• Prime Veramyst nasal spray before first use, when not used for more than 30 days, or if cap has been left off bottle for 5 days or more.

• Administer inhalation powder by oral inhalation only.

Adverse reactions

CNS: Cutivate ointment-lightheadedness; Flonase-headache, dizziness; Flovent-headache, dizziness, giddiness; Veramyst-headache

EENT: Flonase-cataract, glaucoma, increased intraocular pressure, epistaxis, nasal burning or irritation, bloody nasal mucus, runny nose, pharyngitis; Flovent-cataract, glaucoma, nasal congestion, nasal septum perforation, nasal discharge, nasal sinus pain, sinusitis, rhinitis, allergic rhinitis, pharyngitis, dysphonia; Veramyst-cataract, glaucoma, increased intraocular pressure, epistaxis, pharyngolaryngeal pain, nasal ulceration

GI: Flonase-nausea, vomiting, diarrhea, abdominal pain; Flovent-nausea, vomiting, diarrhea, dyspepsia, stomach disorder, oral candidiasis

GU: Flovent-dysmenorrhea

Metabolic: Flovent, Veramyst-hypercorticism and adrenal suppression

Musculoskeletal: Flonase-aches and pains; Flovent-joint pain, limb pain, sprain, strain, aches and pains, reduced bone mineral density; Veramyst-back pain

Respiratory: Flonase-asthma symptoms, cough, bronchitis, wheezing (rare); Flovent-upper respiratory tract infection, influenza, bronchitis, chest congestion, bronchospasm; Veramyst-cough

Skin: Cutivate cream-pruritus, skin dryness, skin burning, erythematous rash, dusky erythema, eczema exacerbation, skin irritation, urticaria; Cutivate ointment-skin burning or irritation, hypertrichosis, increased erythema, hives; Flovent-urticaria, rash, skin eruption

Other: Cutivate cream or ointment-numbness of fingers, facial or nonfacial telangiectasia; Flonase-fever, flulike symptoms, hypersensitivity reaction; Flovent-dental problems, fever, C. albicans infection, immunosuppression, immediate or delayed hypersensitivity reactions, angioedema; anaphylaxis; Veramyst-pyrexia

Interactions

Drug-drug. Ketoconazole, other strong CYP3A inhibitors: increased fluticasone exposure (with Flonase, Flovent, Veramyst)

Ritonavir: increased systemic corticosteroid effects (with Flonase, Flovent, Veramyst)

Drug-diagnostic tests. Adrenocorticotropic hormone stimulation test, plasma cortisol test, urinary free cortisol test: interference with test results

Patient monitoring

Monitor patient for withdrawal symptoms after Flovent is discontinued.

• Stay alert for systemic corticosteroid effects when administering Flovent, Flonase, or Veramyst.

• Observe for reduced growth rate in child or adolescent using Flovent, Flonase, or Veramyst.

• When giving Flovent, watch for eosinophilic conditions, such as Churg-Strauss syndrome.

When giving Flonase, assess for epistaxis, wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure (rare reaction).

When giving Veramyst, assess for epistaxis, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure (rare reaction).

Patient teaching

• Tell patient to take drug exactly as prescribed.

• Teach patient proper use of prescribed form.

Advise patient to immediately report signs of allergic reaction.

• Caution patient to avoid exposure to people with chickenpox or measles.

• Advise female patient taking Flonase, Flovent, or Veramyst to inform prescriber if she is pregnant or breastfeeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

fluticasone propionate

(flo͞o-tĭk′ə-sōn′)
n.
A synthetic corticosteroid used as a topical anti-inflammatory and antipruritic, as a nasal spray in the treatment of rhinitis, and as an inhalant, in combination with salmeterol, in the treatment of asthma and chronic obstructive pulmonary disease.

fluticasone propionate

Flovent®, Rotadisk® Allergy medicine An aqueous nasal spray indicated for treating seasonal and perennial allergic rhinitis in children age 4 and older. See Asthma.

flu·tic·a·sone pro·pi·o·nate

(flū-tikă-sōn prōpē-ŏ-nāt)
Pharmaceutical corticosteroid treatment used to manage nasal symptoms of rhinitis.
References in periodicals archive ?
Trelegy Ellipta is the triple combination therapy of fluticasone furoate, umeclidinium, and vilanterol in a single Ellipta inhaler.
Contract notice: Open house drug discount agreements Vilanterol and fluticasone furoate ATC R03AK10
The researchers randomly assigned 61 people with perennial allergic rhinitis to receive either the intranasal steroid fluticasone furoate (FF) or FF with antioxidants [[beta]-carotene (20 mg/26000 III), ascorbic acid (200 mg), vitamin E (200 mg/200 IU), and selenium (50 [micro]g)] for six weeks.
The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK's Ellipta dry powder inhaler.
A once-daily inhaled combination of fluticasone furoate and vilanterol was associated with an 8% lower rate of exacerbations in chronic obstructive pulmonary disease than was usual care, with no increase in adverse effects, according to a multicenter trial designed to reflect real-world practice.
TABLE 1 Intranasal corticosteroids Aqueous Nonaqueous Beclomethasone (Beconase AQ, Beclomethasone Vancenase AQ) (QNASL Nasal Aerosol) Budesonide (Rhinocort Aqua) Ciclesonide (Zetonna Nasal Aerosol) Ciclesonide (Omnaris) Flunisolide (Nasalide, Nasarel) Fluticasone furoate (Veramyst) Fluticasone propionate (Flonase) Mometasone (Nasonex) Triamcinolone (Nasacort AQ) Fluticasone propionate/azelastine (a) (Dymista) (a) Combination corticosteroid and antihistamine.
Breo Ellipta contains the corticosteroid fluticasone furoate, as well as vilanterol, a long-acting beta-agonist (LABA).
The majority of a Food and Drug Administration advisory panel supported the approval of an inhaled powder formulation of fluticasone furoate and vilanterol as a treatment for chronic obstructive pulmonary disease, based on studies of almost 4,000 patients.
These are beclomethasone dipropionate (Beclate), budesonide (Rhino-cort, Budeflam), triamcinolone (Nasacor), fluticasone dipropionate (Flixonase, Flo-mist), mometasone (Nasonex) and fluticasone furoate (Avamys).
A newer intranasal corticosteroid has been recently introduced, Fluticasone furoate (Veramyst) is thought to have more affinity for the corticosteroid receptor.
This is the first regulatory approval of fluticasone furoate nasal spray, which is also under review under the trade name Allermist in Japan and under the trade name Avamys in Europe, Canada, Australia and other international markets.
It has also been indicated for patients who are on a fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired, or for those who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.